Lassonde's Q2: Margin Boom Masks a Customer Concentration Wound

A Quarter of Offsets

Lassonde's second quarter was a study in countervailing forces. Sales slipped to $738M from $742M, yet gross profit climbed 16% to $228M. Management framed the result as a product of 'effective revenue management, improved product mix, moderating input costs and solid execution of our business strategy.' The margin expansion of 440 bps year‑over‑year came despite persistent category volume declines—particularly in Canadian private label—and a consumer that Vince Timpano describes as 'more mindful of the dollars they have.' The company is navigating a category volume downturn while protecting profit dollars, a tension that defined the call.

The key to the margin beat was lower orange concentrate costs, favorable price adjustments, and a better mix, partly offset by higher PET resin and freight. But management was quick to note that the sustainability of this margin level remains uncertain—a point Francis Trudeau underscored: 'We'll work to keep it for sure, but that's something right now that is very, very volatile.'

The Impairment and the Backfill

The quarter's most significant news was a $30M impairment charge, including $27M tied to a customer relationship in U.S. Specialty Food. The charge stems from a contractual change with a major customer, which led to a reduction in volume. Francis Trudeau explained the rationale: 'When we acquired Summer Garden, we had a significant concentration with one client... the client decided to diversify their risk while continuing our relationship with us.' The company has already secured multiyear contracts to replace more than half of the expected 2027 shortfall, with advanced negotiations for another 25%. This appears to be a deliberate pivot toward lower concentration, even at the cost of near‑term earnings.

Basically, what happened is when we acquired this Summer Garden, we had a significant concentration with one client. And basically, we knew that this agreement would be, at one point, rediscussed... additional capacity was added in the market, and the client decided to diversify their risk.

The impairment is company‑unique and forward‑looking—contractual change and the ensuing backfill plan suggest a strategic shift to derisk the Specialty Food portfolio. The replacement volume already secured signals confidence, but the near‑term hit to sales and profits is real, and management's decision to aggressively backfill rather than accept the loss is notable.

Commodity Whack‑a‑Mole and the Margin Bridge

The gross margin expansion was largely a *falling knife* story—orange concentrate costs are lower, but the Middle East is driving up transportation cost and PET resin prices. As Vince Timpano noted, 'Orange is a portion of our commodities offset by some of the volatility that we continue to see and feel pressure again.' This yo‑yo effect explains why the company refuses to guide on margins and instead emphasizes profit dollars. In prior quarters, management was adamant about the same discipline. On the last call, Eric Gemme reminded analysts: 'We need to focus on margin dollars,' and that message remains central.

The company's hedging strategy has been a recurring theme. On the November 2025 call, Gemme said, 'We are using hedging not as a gamble.' That approach has cushioned the P&L from volatile concentrate prices, but the variable cost environment—freight, resin, fuel—remains a wildcard that could easily erode the current margin tailwind.

Outlook and the NCIB Signal

Despite the strong first half, management revised its 2026 sales outlook to *slightly below* last year's level, citing private‑label softness, the intentional discontinuation of low‑margin lines, and a tougher comparison against the Buy Canadian surge. The top‑line caution is balanced by a newly announced normal course issuer bid to repurchase up to 200,000 Class A shares (~6.5% of outstanding). Francis Trudeau framed the timing as a function of the CapEx cycle winding down: 'We see now it's a good timing in the next 12 months... we are able to do this buyback.' This marks the first buyback in years and signals conviction in the shares despite a softer near‑term outlook.

What changed at Lassonde is not a single pivot but a recalibration: the company is trading margin‑negative volume for portfolio resilience, accepting a temporary earnings hit to reduce customer concentration, and simultaneously returning capital while guiding sales lower. The next few quarters will test whether the backfill can offset the lost volume and whether the commodity tailwind persists against structural cost pressures.